Orthocell (ASX:OCC) has secured $30 million through an institutional placement to accelerate the global commercialisation of its flagship nerve repair product and expand its regenerative medicine portfolio.
The company stated it attracted significant domestic and international investor interest, including new US institutional investors, positioning it with more than $50 million in cash and no debt.
Chief Executive Officer and Managing Director Paul Anderson described the raise as a strategic shift to build on strong commercial momentum. “We have built significant momentum in the commercialisation of Remplir and the funds from the capital raising will be focapplyd on accelerating that process,” he stated. “We greatly appreciate the support we have received from new and existing institutional and high net worth investors and particularly welcome our new investors from the US.”
The funds will be directed toward several priorities, including scaling up US sales of Remplir, expanding manufacturing capacity at its Western Australian facility, progressing clinical studies in prostate cancer surgery, and advancing applications in tconcludeon, ligament and bone repair. The capital will also support new research into emerging regenerative medicine technologies.
The company stated the US commercial rollout of Remplir, launched after FDA clearance in April 2025, is ahead of schedule. The company’s specialist distributor network now spans 25 states, covering 40 per cent of the US population. More than 40 surgeries have been completed across multiple hospitals, and over 100 surgeons have been introduced to the product. Orthocell has also secured 11 hospital approvals through Value Analysis Committees, with additional applications underway. Revenue from the US is expected to launch ramping up in the December quarter.
Remplir has already achieved six consecutive quarters of record revenue in existing markets, reaching $3 million in the September quarter, without a significant US contribution. “That means we’re in a position of strength and our capital raising is all about driving our growth plans,” Anderson stated. “We’re particularly focapplyd on the potential for Remplir to be applyd in prostate cancer surgeries and will be investing further to support the work we’ve already done to date.”
The placement, managed by Canaccord Genuity, involved the issue of 23,076,923 new shares at $1.30 per share, a 9.1 per cent discount to the last traded price, reflecting strong market demand.
Leave a Reply